Mitumprotimut T

N/A

Report date: 2023/05/05 17:34:42

Base Information

Drug NameMitumprotimut T
Drug Alias NameB cell lymphoma vaccine - FavrilleId-KLH vaccineSpecifidFavIdNon-Hodgkin's lymphoma vaccine - Favrille
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator modulatorsImmunostimulants
TargetsB-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsLymphoma, FollicularLymphoma, B-CellLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMmrglobal
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMmrglobalNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLymphoma, FollicularLymphoma, B-CellLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG